P. Iversen

发表

O. J. Trask, G. Sittampalam, N. Coussens, 2004 .

The Minimum Significant Ratio: A Statistical Parameter to Characterize the Reproducibility of Potency Estimates from Concentration-Response Assays and Estimation by Replicate-Experiment Studies

Kim E. Garbison, Mark W Farmen, Brian J Eastwood, 2006, Journal of biomolecular screening.

A Comparison of Assay Performance Measures in Screening Assays: Signal Window, Z' Factor, and Assay Variability Ratio

Brian J Eastwood, G. Sittampalam, P. Iversen, 2006, Journal of biomolecular screening.

Translational Framework Predicting Tumour Response in Gemcitabine-Treated Patients with Advanced Pancreatic and Ovarian Cancer from Xenograft Studies

P. Iversen, I. Trocóniz, C. Pitou, 2019, The AAPS Journal.

Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations

P. Iversen, G. Plowman, Y. Webster, 2017, Clinical Cancer Research.

Thigh Model of Infection in the Neutropenic Mouse Escherichia coli Imaging Technology Using Bioluminescent Validation of a Noninvasive , Real-Time

P. Iversen, D. Jenkins, P. R. Contag, 2000 .

A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer

T. Zander, Michael Thomas, P. Iversen, 2019, Investigational New Drugs.

Antisense Inhibition of Survivin Expression as a Cancer Therapeutic

P. Iversen, G. Sandusky, N. Stamm, 2011, Molecular Cancer Therapeutics.

Castration triggers growth of previously static androgen‐independent lesions in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model

P. Iversen, G. Sandusky, J. Graff, 2005, The Prostate.

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

K. Cole, J. Maris, B. Teicher, 2018, Clinical Cancer Research.

Characterizing Gemcitabine Effects Administered as Single Agent or Combined with Carboplatin in Mice Pancreatic and Ovarian Cancer Xenografts: A Semimechanistic Pharmacokinetic/Pharmacodynamics Tumor Growth-Response Model

P. Iversen, I. Trocóniz, C. Pitou, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Protein kinase C βII activation induces angiotensin converting enzyme expression in neonatal rat cardiomyocytes

P. Iversen, C. Vlahos, Lan Yu, 2003 .

Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer.

J. Herman, E. Gabrielson, F. Parl, 2000, Cancer research.

LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice

B. Teicher, P. Iversen, Yun-Fei Chen, 2004, Cancer Chemotherapy and Pharmacology.

Selectivity data: assessment, predictions, concordance, and implications.

Ian A. Watson, M. Vieth, P. Iversen, 2013, Journal of medicinal chemistry.

Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth

P. Iversen, V. Wacheck, M. Mader, 2016, Molecular Cancer Therapeutics.

Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling

P. Houghton, P. Iversen, Simone Gupta, 2018, Clinical Cancer Research.

Dynamic Graphical Tools for Teaching Experimental Design and Analysis Concepts

M. Marasinghe, P. Iversen, 2001 .

Pharmacodynamics of Oritavancin (LY333328) in a Neutropenic-Mouse Thigh Model of Staphylococcus aureus Infection

P. Iversen, M. Zeckel, K. Campanale, 2003, Antimicrobial Agents and Chemotherapy.

Infection Staphylococcus aureus Model of ( LY 333328 ) in a Neutropenic-Mouse Thigh Pharmacodynamics of Oritavancin

P. Iversen, M. Zeckel, K. Campanale, 2003 .

Pharmacodynamics of Oritavancin ( LY 333328 ) in a Neutropenic-Mouse Thigh Model of Staphylococcus aureus Infection

P. Iversen, M. Zeckel, K. Campanale, 2003 .

Advances in Brief Aberrant Methylation of the Estrogen Receptor and E-Cadherin 5 * CpG Islands Increases with Malignant Progression in Human Breast Cancer 1

J. Herman, E. Gabrielson, F. Parl, 2000 .

Cardiomyocyte Impedance Assays -- Assay Guidance Manual

N. Coussens, H. Nelson, M. Arkin, 2004 .

Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3.

R. Campbell, P. Iversen, M. Clay, 2004, Journal of medicinal chemistry.

Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.

N. Sonenberg, J. Pelletier, P. Iversen, 2011, Cancer research.

Transgenic mice with cardiac-specific over-expression of MLK7 have increased mortality when exposed to chronic beta-adrenergic stimulation.

P. Iversen, Xiaohong Yu, J. Lorenz, 2004, Journal of molecular and cellular cardiology.

Assay Development for Protein Kinase Enzymes -- Assay Guidance Manual

C. Austin, N. Coussens, M. Arkin, 2004 .

Nonclinical Assessment of Carcinogenic Risk and Tumor Growth Enhancement Potential of Prasugrel, a Platelet-Inhibiting Therapeutic Agent

A. Sanbuissho, P. Iversen, L. Buckley, 2012, International journal of toxicology.

Systematic Modeling and Design Evaluation of Unperturbed Tumor Dynamics in Xenografts

Zinnia P. Parra-Guillen, P. Iversen, I. Trocóniz, 2018, The Journal of Pharmacology and Experimental Therapeutics.

Visualizing Experimental Designs for Balanced ANOVA Models using Lisp-Stat

Mervyn G. Marasinghe, Philip W. Iversen, M. Marasinghe, 2004 .

Dynamic graphics for experimental design

Philip W. Iversen, P. Iversen, 1993 .

Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents.

G. Durst, P. Hipskind, B. Teicher, 2004, Journal of medicinal chemistry.

Cell Viability Assays -- Assay Guidance Manual

Christopher P. Austin, James Inglese, Sittampalam Gs, 2004 .

Protein Kinase C Isozymes Differentially Regulate Promoters Containing PEA-3/12-O-Tetradecanoylphorbol-13-acetate Response Element Motifs*

D. Burns, P. Iversen, D. M. Conarty, 1996, The Journal of Biological Chemistry.

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade.

E. Rasmussen, P. Iversen, M. Kalos, 2018, Cell reports.

HTS Assay Validation

S. Iturria, V. Devanarayan, M. Farmen, 2012 .

Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib.

C. Caldwell, P. Iversen, Jian Du, 2017, Cancer cell.

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

P. Iversen, L. Gelbert, Concha Sánchez-Martínez, 2014, Investigational New Drugs.

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

P. Iversen, M. Kalos, G. Plowman, 2018, Journal of Immunotherapy for Cancer.

Authentication of Human Cell Lines by STR DNA Profiling Analysis -- Assay Guidance Manual

James Inglese, Sittampalam Gs, Michelle R. Arkin, 2013 .

Assay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid Cultures

Dirk Schumacher, Rubén Haro, Philip W. Iversen, 2016, Journal of biomolecular screening.

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

Xiaohong Xu, Philip W. Iversen, David K. Clawson, 2017, Oncotarget.

The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts

R. Campbell, P. Iversen, J. Graff, 2005 .

Validation of a Noninvasive, Real-Time Imaging Technology Using Bioluminescent Escherichia coli in the Neutropenic Mouse Thigh Model of Infection

P. Iversen, D. Jenkins, P. R. Contag, 2001, Antimicrobial Agents and Chemotherapy.

In Vivo Assay Guidelines

S. Iturria, P. Iversen, Hui-Rong Qian, 2004 .

Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators.

Shengfang Jin, P. Iversen, M. Rolfe, 2005, Cancer research.

Cloning and functional characterization of the multidrug resistance-associated protein (MRP1/ABCC1) from the cynomolgus monkey.

P. Iversen, Xiaoling Xia, A. Dantzig, 2003, Molecular cancer therapeutics.

Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors.

P. Iversen, L. Platanias, J. Graff, 2013, Blood.

Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene.

Huimin Bian, Shaoyou Chu, Anna Pustilnik, 2018, Cancer discovery.

Human Carboxylesterase-2 Hydrolyzes the Prodrug of Gemcitabine (LY2334737) and Confers Prodrug Sensitivity to Cancer Cells

Philip W. Iversen, Robert L. Shepard, P. Iversen, 2013, Clinical Cancer Research.

Assay Development Guidelines for Image-Based High Content Screening, High Content Analysis and High Content Imaging -- Assay Guidance Manual

James Inglese, Sittampalam Gs, Nathan P. Coussens, 2014 .

Elevated Expression of Angiogenin in Prostate Cancer and Its Precursors

Liang Cheng, P. Iversen, Shaobo Zhang, 2005, Clinical Cancer Research.

Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology

B. Teicher, P. Iversen, Yun-Fei Chen, 2003, Cancer Chemotherapy and Pharmacology.

Characterization of a novel AICARFT inhibitor which potently elevates ZMP and has anti-tumor activity in murine models

P. Iversen, Y. Qian, Matthew R. Lee, 2018, Scientific Reports.

Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer

P. Iversen, M. Marshall, D. Barnard, 2014, Investigational New Drugs.

Assay Guidance Manual: Quantitative Biology and Pharmacology in Preclinical Drug Discovery

Sam Michael, Anton Simeonov, Menghang Xia, 2018, Clinical and translational science.

A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib

P. Iversen, J. Dempsey, R. Beckmann, 2020, Oncotarget.

Pharmacokinetics and Drug Metabolism

C. Austin, O. J. Trask, G. Sittampalam, 2004 .

Assay Interference by Chemical Reactivity -- Assay Guidance Manual

James Inglese, Sittampalam Gs, Michelle R. Arkin, 2004 .

In vitro 3D Spheroids and Microtissues: ATP-based Cell Viability and Toxicity Assays -- Assay Guidance Manual

Christopher P. Austin, James Inglese, Sittampalam Gs, 2004 .

Minimum Significant Ratio – A Statistic to Assess Assay Variability -- Assay Guidance Manual

C. Austin, N. Coussens, M. Arkin, 2013 .

Abstract 3259: LY3127804, a novel anti-Angiopoietin-2 antibody in combination with an anti-VEGFR2 antibody potently inhibits angiogenesis, tumor growth and metastasis

P. Iversen, L. Benjamin, V. Wacheck, 2016 .

Properties of bisphosphonates in the 13762 rat mammary carcinoma model of tumor-induced bone resorption.

B. Teicher, P. Iversen, T. Martin, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Genome Editing Using Engineered Nucleases and Their Use in Genomic Screening -- Assay Guidance Manual

Jayme L. Dahlin, Devanaryan, Timothy L. Foley, 2004 .

Basics of Enzymatic Assays for HTS -- Assay Guidance Manual

C. Austin, N. Coussens, M. Arkin, 2004 .

FLIPR™ Assays for GPCR and Ion Channel Targets -- Assay Guidance Manual

Jayme L. Dahlin, Devanaryan, Timothy L. Foley, 2012 .

Advanced Assay Development Guidelines for Image-Based High Content Screening and Analysis -- Assay Guidance Manual

Christopher P. Austin, James Inglese, Sittampalam Gs, 2004 .

Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.

P. Iversen, L. Vignati, J. Anderson, 1997, Clinical therapeutics.

Characterization of a novel AICARFT inhibitor which potently elevates ZMP and has anti-tumor activity in murine models

P. Iversen, Y. Qian, Matthew R. Lee, 2018, Scientific Reports.

Design of Signal Windows in High Throughput Screening Assays for Drug Discovery

G. Sitta Sittampalam, Steven D. Kahl, Philip W. Iversen, 1997 .

HTS technologies to facilitate chemical genomics

Christopher P. Austin, James Inglese, James McGee, 2007 .

Histone Acetyltransferase Assays in Drug and Chemical Probe Discovery -- Assay Guidance Manual

Jayme L. Dahlin, Devanaryan, Timothy L. Foley, 2018 .

Automated Electrophysiology Assays -- Assay Guidance Manual

Menghang Xia, Christopher P. Austin, James Inglese, 2004 .

HTS Assay Validation -- Assay Guidance Manual

C. Austin, N. Coussens, M. Arkin, 2004 .

Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.

N. Sonenberg, J. Pelletier, P. Iversen, 2011, Cancer research.

Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats.

R. Higgs, D. Burr, I. Owan, 1996, The Journal of pharmacology and experimental therapeutics.

Interference with Fluorescence and Absorbance -- Assay Guidance Manual

Christopher P. Austin, James Inglese, Sittampalam Gs, 2004 .

Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F

P. Iversen, R. Walgren, B. Zhao, 2013, Blood Cancer Journal.

Human Carboxylesterase-2 Hydrolyzes the Prodrug of Gemcitabine (LY2334737) and Confers Prodrug Sensitivity to Cancer Cells

P. Iversen, A. Dantzig, R. Shepard, 2013, Clinical Cancer Research.